Kirk Shepard, MD
Allergy & Immunology · Chicago, ILNPI 1982022810
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.3%), consulting fees and education — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Regeneron at 43.8% of the total. 2025 is the largest year on record at $4,274, more than ten times the $377 reported in 2019.
Across 191 payments — averaging $39.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$3K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$1K
- AstraZeneca$496
- GSK$437
- Novartis$158
- plus $874 from 13 others
Across 3 payments — averaging $4361.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$7K
- GSK$6K
What the payments were for
- Consulting fees$3,19842%
- Food & beverage$4,11754%
- Education$2694%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 4 | $3,325 |
| Sanofi | 54 | $1,250 |
| Regeneron Healthcare Solutions, Inc. | 42 | $1,045 |
| AstraZeneca | 21 | $496 |
| GSK | 25 | $437 |
| Novartis | 3 | $158 |
| Optinose US, Inc. | 12 | $152 |
| Genentech USA, Inc. | 6 | $134 |
| Alk-abello, Inc | 5 | $111 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $87 |
| Amgen | 5 | $80 |
| Inspire Medical Systems, Inc. | 2 | $51 |
| Smith+Nephew | 2 | $48 |
| CSL Behring | 2 | $47 |
| Pfizer | 1 | $21 |
| Biocryst US Sales Co., LLC | 1 | $21 |
| Shire North American Group Inc | 1 | $16 |
| Kaleo, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,584 in reported general payments places this provider in the 70th percentile of 161 allergy & immunology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 29 | $139,050 |
| Dupixent SyringeDupilumab | 12 | $55,032 |
| Spiriva RespimatTiotropium Bromide | 16 | $8,973 |
| Azelastine Hcl | 92 | $4,324 |
| Ipratropium Bromide | 87 | $2,340 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 12 | $1,836 |
| Olopatadine Hcl | 11 | $1,686 |
| Fluticasone Propionate | 103 | $1,340 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $748 |
| Montelukast Sodium | 84 | $558 |
| Levocetirizine Dihydrochloride | 20 | $250 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Chicago
- Anju PetersChicago$563K
- Giselle MosnaimChicago$331K
- Amanda SalihChicago$160K
- Juanita MoraChicago$147K
- Christina CiaccioChicago$73K
- Michael FoggsChicago$71K
- Melanie MakhijaChicago$56K
- Whitney StevensChicago$34K
- Andrea Pappalardo WlochowiczChicago$33K
- Krishan ChhibaChicago$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.